Bafna Pharmaceuticals Limited (NSEI: BAFNAPH)
Health Care · Pharmaceuticals · IN
Rs242.45
-5.92% today · +153.5% 1Y
Bafna Pharmaceuticals Limited (NSEI: BAFNAPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $59.94M and employs 406 people.
Over the last twelve months the share price has gained 153.5%, trading between 91.20 and 290.70.
Tweenvest scores Bafna Pharmaceuticals Limited across four factors: quality 63/100, value 30/100, growth 25/100. Its strongest factor is quality.
BAFNAPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $59.94M
- Revenue (TTM)
- $15.08M
- P/E
- 74.74
- EPS
- 3.24
- Dividend yield
- —
- Beta (5Y)
- 0.08
- 52-week high
- Rs290.70
- 52-week low
- Rs91.20
- Avg volume (3M)
- —
- Shares outstanding
- 23.66M
- Employees
- 406
- Next earnings
- —
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
- ISIN
- INE878I01022
- Founded
- 1981
- Listed since
- Dec 28, 2005
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.